NY-SCHRÖDINGER
8.1.2020 13:02:05 CET | Business Wire | Press release
Schrödinger and Bayer (BAYN: DE) today announced a five-year technology alliance to develop a comprehensive de novo design solution with the objective to accelerate the discovery of innovative high-quality drugs. The technology is expected to be capable of enumerating, screening, and scoring billions of synthetically feasible, virtual compounds supporting the identification and optimization of potential new therapeutic candidates. Under the terms of the agreement, Schrödinger is expected to receive about €10 million.
The de novo design software will integrate the power of Schrödinger’s molecular design technology, which relies on physics-based modeling augmented by machine learning, with Bayer’s proprietary in silico models predicting compound absorption, distribution, metabolism, excretion, toxicity (ADMET) and chemical synthesizability. The new software will be built on Schrödinger’s enterprise informatics solution, LiveDesign, and is intended to rapidly design large numbers of molecules and predict their properties.
“Underscoring our efforts in digital transformation along our value chain, our collaboration with Schrödinger is intended to leverage advanced physics-based methods and modern machine learning capabilities to increase discovery of viable drug candidates,” said Dr. Karl Ziegelbauer, Head of Open Innovation & Digital Technologies at the Pharmaceuticals Division of Bayer AG. “The new co-developed technological solution is aimed at opening up new avenues for therapeutic discovery in the future, ultimately for the benefit of the patients.”
“We admire Bayer’s passion for innovation and commitment to leverage cutting-edge technology to overcome global health challenges,” said Schrödinger CEO Ramy Farid, Ph.D. “Our mission statement echoes those goals, and we are proud to realize that vision through this collaboration. The de novo design solution, built on the complementary strengths of Schrödinger and Bayer, holds the promise of accelerating the discovery of novel medicines for important unmet needs.”
About Schrödinger
Schrödinger’s industry-leading
computational platform to accelerate drug discovery and materials design
is deployed by leading biopharmaceutical and industrial companies,
academic institutions and government laboratories worldwide. In addition
to this global business, Schrödinger is also applying its computational
platform to a robust pipeline of drug discovery programs in
collaboration with pharmaceutical companies and has co-founded leading
biotech companies, including Nimbus Therapeutics. In addition,
Schrödinger is using its platform to advance a pipeline of internal,
wholly-owned drug discovery programs. Schrödinger’s significant and
ongoing investment in basic research continues to drive advances in its
computational platform. Founded in 1990, Schrödinger has over 400
employees in its New York City headquarters and around the world. Visit
www.schrodinger.com for more information.
About Bayer
Bayer is a global enterprise with core
competencies in the life science fields of health care and nutrition.
Its products and services are designed to benefit people by supporting
efforts to overcome the major challenges presented by a growing and
aging global population. At the same time, the Group aims to increase
its earning power and create value through innovation and growth. Bayer
is committed to the principles of sustainable development, and the Bayer
brand stands for trust, reliability and quality throughout the world. In
fiscal 2018, the Group employed around 117,000 people and had sales of
39.6 billion euros. Capital expenditures amounted to 2.6 billion euros,
R&D expenses to 5.2 billion euros. For more information, go to
www.bayer.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200108005059/en/
Contact:
Schrödinger Media Contact: Stephanie Simon Ten Bridge Communications stephanie@tenbridgecommunications.com 617-581-9333 Schrödinger Investor Contact: Christina Tartaglia Stern IR, Inc. christina.tartaglia@sternir.com 212-362-1200
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release
Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
SLB Announces Date for Second-Quarter 2026 Results Conference Call26.5.2026 19:00:00 CEST | Press release
SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/157027565 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 31, 2026, and can be accessed by dialing +1 (800) 770-2030 within North America or +1
Alipay Launches Next-Generation AI Payment Infrastructure, Debuts AI Wallet and Token Pay to Power Agentic Economy26.5.2026 17:20:00 CEST | Press release
Alipay today introduced its full-stack AI payment solution to partners across industries, ranging from AI companies to traditional retailers, and debuted two new services — the world’s first AI Wallet and Token Pay — to support the agentic economy’s rapid growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526337824/en/ Alipay Unveils Next-generation AI Payment Infrastructure This launch extends Alipay's next-generation AI payment infrastructure, building on its consumer-facing product Alipay AI Pay and its business-facing AI payment processing product. “While the essence of commerce remains unchanged in the age of AI, the emergence of AI agents is reshaping everything. Drawing on 22 years of technological expertise and commercial know-how, Alipay is building a new generation of AI payment services to accelerate the growth of the agentic commerce ecosystem,” said Cyril Han, CEO of Ant Group. AI Wallet: Giving Users Vis
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom